312 related articles for article (PubMed ID: 23686837)
1. Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.
Filosto S; Baston DS; Chung S; Becker CR; Goldkorn T
Mol Cancer Ther; 2013 Aug; 12(8):1579-90. PubMed ID: 23686837
[TBL] [Abstract][Full Text] [Related]
2. Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.
Filosto S; Becker CR; Goldkorn T
Mol Cancer Ther; 2012 Apr; 11(4):795-804. PubMed ID: 22302097
[TBL] [Abstract][Full Text] [Related]
3. Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT.
Li D; Zhang L; Zhou J; Chen H
Lung Cancer; 2016 Mar; 93():35-42. PubMed ID: 26898612
[TBL] [Abstract][Full Text] [Related]
4. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
[TBL] [Abstract][Full Text] [Related]
5. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
[TBL] [Abstract][Full Text] [Related]
6. Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC.
Cheng FJ; Chen CH; Tsai WC; Wang BW; Yu MC; Hsia TC; Wei YL; Hsiao YC; Hu DW; Ho CY; Li TS; Wu CY; Chou WY; Yu YL; Tang CH; Chen CY; Chen CM; Hsu JL; Chen HF; Chen Y; Tu CY; Hung MC; Huang WC
Oncogene; 2021 Feb; 40(6):1162-1175. PubMed ID: 33335306
[TBL] [Abstract][Full Text] [Related]
7. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
[TBL] [Abstract][Full Text] [Related]
8. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
10. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Fong JT; Jacobs RJ; Moravec DN; Uppada SB; Botting GM; Nlend M; Puri N
PLoS One; 2013; 8(11):e78398. PubMed ID: 24223799
[TBL] [Abstract][Full Text] [Related]
11. Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling.
Ye M; Zhang Y; Gao H; Xu Y; Jing P; Wu J; Zhang X; Xiong J; Dong C; Yao L; Zhang J; Zhang J
Clin Cancer Res; 2018 Mar; 24(5):1227-1239. PubMed ID: 29229632
[No Abstract] [Full Text] [Related]
12. Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer.
Yang YC; Pan KF; Lee WJ; Chang JH; Tan P; Gu CC; Chang WM; Yang SF; Hsiao M; Hua KT; Chien MH
Cancer Res; 2020 Aug; 80(16):3292-3304. PubMed ID: 32561533
[TBL] [Abstract][Full Text] [Related]
13. Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs.
Tu CY; Cheng FJ; Chen CM; Wang SL; Hsiao YC; Chen CH; Hsia TC; He YH; Wang BW; Hsieh IS; Yeh YL; Tang CH; Chen YJ; Huang WC
Mol Oncol; 2018 May; 12(5):705-723. PubMed ID: 29570930
[TBL] [Abstract][Full Text] [Related]
14. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N
Cells; 2022 May; 11(10):. PubMed ID: 35626731
[TBL] [Abstract][Full Text] [Related]
15. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
[TBL] [Abstract][Full Text] [Related]
16. Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
Patel MR; Jay-Dixon J; Sadiq AA; Jacobson BA; Kratzke RA
J Thorac Oncol; 2013 Sep; 8(9):1142-7. PubMed ID: 23883783
[TBL] [Abstract][Full Text] [Related]
17. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
18. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X
Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157
[TBL] [Abstract][Full Text] [Related]
19. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
